Pancreatic Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Pancreatic Cancer Therapeutics and Diagnostics Market Report is Segmented by Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments) and Diagnostics (Imaging, Biopsy, Endoscopic Ultrasound, and Other Diagnostics)) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Pancreatic Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Pancreatic Cancer Therapeutics and Diagnostics Market Size

Pancreatic Cancer Therapeutics and Diagnostics Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 4.90 Billion
Market Size (2030) USD 7.05 Billion
CAGR (2025 - 2030) 7.52 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Pancreatic Cancer Therapeutics and Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Pancreatic Cancer Therapeutics And Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Pancreatic Cancer Therapeutics and Diagnostics Market Analysis

The Pancreatic Cancer Therapeutics And Diagnostics Market size is estimated at USD 4.90 billion in 2025, and is expected to reach USD 7.05 billion by 2030, at a CAGR of 7.52% during the forecast period (2025-2030).

Pancreatic cancer therapeutics and diagnostics involve medical procedures for diagnosing pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, drug development, and pancreatic cancer diagnostic technology play a major part in pancreatic cancer market growth. With the increase in research and development initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period. For instance, according to the Australian Pancreatic Cancer Foundation Statistics published in 2023, pancreatic cancer was diagnosed in 4,506 patients in 2023. Pancreatic cancer was the eighth most prevalent disease diagnosed in Australia in 2023. Thus, the growing burden of pancreatic cancer is expected to boost the demand for effective diagnosis and treatment, which is likely to propel the growth of the pancreatic cancer treatment market during the forecast period. Rising research and development activities for pancreatic cancer medication, as well as a large product pipeline, may increase product approval by regulatory authorities, increasing the accessibility and availability of a greater number of drugs to treat pancreatic cancer and contributing to pancreatic cancer treatment drugs market growth. For instance, in February 2023, updated results of the fully enrolled cohort of the phase 2 QUILT 88 study (NCT03563144) showed a doubling of survival in third-line patients with metastatic pancreatic cancer when treated with the novel combination immunotherapy protocol of low-dose chemoradiation, N-803, and PDL1 t-haNK therapy. These promising results may have significant implications for the metastatic pancreatic cancer market. Also, in April 2023, Cantargia reported new findings from the phase I/IIa clinical trial CANFOUR, designed to evaluate nadunolimab in combination with chemotherapy for treating pancreatic cancer. Patients with high tumor levels of IL1RAP benefit from nadunolimab treatment. Hence, promising clinical trial studies lead to product approvals, which are expected to drive the market during the forecast period. Thus, all aforementioned factors, such as the increasing prevalence of pancreatic cancer and rising research and development activities, are expected to boost the market growth during the forecast period. However, the high cost of diagnosis and treatment may restrain the growth of the pancreatic cancer therapeutics and diagnostics market during the forecast period.

Pancreatic Cancer Therapeutics and Diagnostics Industry Overview

The pancreatic cancer therapeutics market is highly competitive, with many key players dominating the market. The presence of major market players like Novartis AG, Pfizer Inc., Immunovia AB, AstraZeneca PLC, Myriad Genetics Inc., and Viatris Inc. is intensifying the competition. The market players are adopting strategies, such as increasing R&D investments in pancreatic cancer drugs, mergers, acquisitions, and product innovations, to sustain the increasing competition in the market.

Pancreatic Cancer Therapeutics and Diagnostics Market Leaders

  1. Myriad Genetics, Inc.

  2. Pfizer, Inc

  3. Novartis AG

  4. AstraZeneca plc

  5. Immunovia AB

  6. *Disclaimer: Major Players sorted in no particular order
Pancreatic Cancer Therapeutics and Diagnostics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Pancreatic Cancer Therapeutics and Diagnostics Market News

  • February 2024: The United States Food and Drug Administration approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. The approval was based on NAPOLI 3 (NCT04083235), a randomized study that assessed the drug's efficacy among metastatic pancreatic adenocarcinoma patients.
  • January 2024: The United States Food and Drug Administration cleared an investigational new drug (IND) application for ACT-IOP-003, an implantable iontophoretic product, as a potential treatment for patients with pancreatic cancer, and a phase 1b trial of the agent plans to start mid-2024.

Pancreatic Cancer Therapeutics And Diagnostics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
    • 4.2.2 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Diagnosis and Treatments
    • 4.3.2 Stringent Regularity Guidelines
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value – USD)

  • 5.1 By Type
    • 5.1.1 Treatment
    • 5.1.1.1 Targeted Therapies
    • 5.1.1.2 Chemotherapy
    • 5.1.1.3 Surgery
    • 5.1.1.4 Other Treatments
    • 5.1.2 Diagnostics
    • 5.1.2.1 Imaging
    • 5.1.2.2 Biopsy
    • 5.1.2.3 Endoscopic Ultrasound
    • 5.1.2.4 Other Diagnostics
  • 5.2 By End User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 United Kingdom
    • 5.3.2.2 Germany
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Myriad Genetics Inc.
    • 6.1.2 Novartis AG
    • 6.1.3 ClearNote Health
    • 6.1.4 AstraZeneca PLC
    • 6.1.5 Prestige Biopharma
    • 6.1.6 Boston Scientific Corporation
    • 6.1.7 FUJIFILM Holdings Corporation
    • 6.1.8 Canon Inc. (Canon Medical Systems Corporation)
    • 6.1.9 Immunovia AB
    • 6.1.10 Apexigen Inc.
    • 6.1.11 Pfizer Inc
    • 6.1.12 F Hoffmann-La Roche AG
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pancreatic Cancer Therapeutics and Diagnostics Industry Segmentation

As per the scope, pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine based on the cells affected by cancer. The pancreatic cancer therapeutics and diagnostics market is segmented by type, end user, and geography. By type, the market is segmented into treatment (targeted therapies, chemotherapy, surgery, and other treatments) and diagnostics (imaging, biopsy, endoscopic ultrasound, and other diagnostics). By end user, the market is segmented into hospitals, clinics, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Type Treatment Targeted Therapies
Chemotherapy
Surgery
Other Treatments
Diagnostics Imaging
Biopsy
Endoscopic Ultrasound
Other Diagnostics
By End User Hospitals and Clinics
Other End Users
Geography North America United States
Canada
Mexico
Europe United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Pancreatic Cancer Therapeutics And Diagnostics Market Research Faqs

How big is the Pancreatic Cancer Therapeutics And Diagnostics Market?

The Pancreatic Cancer Therapeutics And Diagnostics Market size is expected to reach USD 4.90 billion in 2025 and grow at a CAGR of 7.52% to reach USD 7.05 billion by 2030.

What is the current Pancreatic Cancer Therapeutics And Diagnostics Market size?

In 2025, the Pancreatic Cancer Therapeutics And Diagnostics Market size is expected to reach USD 4.90 billion.

Who are the key players in Pancreatic Cancer Therapeutics And Diagnostics Market?

Myriad Genetics, Inc., Pfizer, Inc, Novartis AG, AstraZeneca plc and Immunovia AB are the major companies operating in the Pancreatic Cancer Therapeutics And Diagnostics Market.

Which is the fastest growing region in Pancreatic Cancer Therapeutics And Diagnostics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Pancreatic Cancer Therapeutics And Diagnostics Market?

In 2025, the North America accounts for the largest market share in Pancreatic Cancer Therapeutics And Diagnostics Market.

What years does this Pancreatic Cancer Therapeutics And Diagnostics Market cover, and what was the market size in 2024?

In 2024, the Pancreatic Cancer Therapeutics And Diagnostics Market size was estimated at USD 4.53 billion. The report covers the Pancreatic Cancer Therapeutics And Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pancreatic Cancer Therapeutics And Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Pancreatic Cancer Therapeutics And Diagnostics Industry Report

Statistics for the 2025 Pancreatic Cancer Therapeutics And Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pancreatic Cancer Therapeutics And Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.